Symbols / ITRM
ITRM Chart
About
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.97M |
| Enterprise Value | 35.58M | Income | -26.96M | Sales | 390.00K |
| Book/sh | -0.15 | Cash/sh | 0.21 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -0.37 | PEG | — |
| P/S | 33.25 | P/B | -1.61 | P/C | — |
| EV/EBITDA | -1.84 | EV/Sales | 91.22 | Quick Ratio | 1.80 |
| Current Ratio | 2.13 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.85 | EPS next Y | -0.66 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -53.28% |
| ROE | — | ROIC | — | Gross Margin | 29.74% |
| Oper. Margin | -19.82% | Profit Margin | 0.00% | Shs Outstand | 53.29M |
| Shs Float | 52.37M | Short Float | 3.71% | Short Ratio | 2.35 |
| Short Interest | — | 52W High | 1.53 | 52W Low | 0.20 |
| Beta | 2.94 | Avg Volume | 739.04K | Volume | 2.34M |
| Target Price | $5.50 | Recom | None | Prev Close | $0.20 |
| Price | $0.24 | Change | 20.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.50
Mean price target
2. Current target
$0.24
Latest analyst target
3. DCF / Fair value
$-4.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.24
Low
$2.00
High
$9.00
Mean
$5.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-15 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-21 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-31 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-02-07 | up | HC Wainwright & Co. | Neutral → Buy | $6 |
- New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan Wed, 17 Dec 2025 08
- Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before Long - Yahoo Finance Fri, 17 Oct 2025 07
- $ITRM stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Fri, 14 Nov 2025 08
- Iterum Therapeutics Shareholders Reject Key Capital Proposals - TipRanks Wed, 18 Feb 2026 23
- Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before Long - simplywall.st hu, 04 Sep 2025 07
- Iterum Therapeutics (NASDAQ: ITRM) flags going‑concern risk after failed capital votes - Stock Titan Wed, 18 Feb 2026 22
- Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com ue, 12 Aug 2025 07
- Iterum Therapeutics PLC (NASDAQ:ITRM) Stock Plummets on Wider-Than-Expected Q3 Loss - ChartMill Fri, 14 Nov 2025 08
- Iterum Therapeutics Stock (ITRM) Opinions on Awaiting FDA Decision | ITRM Stock News - Quiver Quantitative ue, 12 Aug 2025 07
- Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance Sat, 10 May 2025 07
- Iterum Therapeutics launches $20 million at-the-market share offering - Investing.com hu, 16 Oct 2025 07
- Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 - Stock Titan Fri, 05 Dec 2025 08
- Iterum Therapeutics Announces $20M Share Offering - TipRanks hu, 16 Oct 2025 07
- ITERUM THERAPEUTICS Earnings Preview: Recent $ITRM Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 12 Nov 2025 08
- Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com Wed, 17 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6000 | 2191.0 | — | Purchase at price 0.37 per share. | DUNNE MICHAEL W | Director | — | 2025-11-18 00:00:00 | D |
| 1 | 15000 | 10854.0 | — | Purchase at price 0.72 per share. | DUNNE MICHAEL W | Director | — | 2025-08-08 00:00:00 | D |
| 2 | 247934 | nan | — | — | HUNT RONALD M | Director | — | 2024-08-06 00:00:00 | I |
| 3 | 82613 | nan | — | — | FISHMAN COREY N | Chief Executive Officer | — | 2024-08-06 00:00:00 | D |
| 4 | 106247 | 128559.0 | — | Conversion of Exercise of derivative security at price 1.21 per share. | DUNNE MICHAEL W | Director | — | 2024-08-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -408.62K | 1.38M | 682.25K | -7.62M |
| TaxRateForCalcs | 0.12 | 0.12 | 0.12 | 0.12 |
| NormalizedEBITDA | -18.46M | -45.64M | -45.43M | -22.24M |
| TotalUnusualItems | -3.27M | 11.06M | 5.46M | -60.96M |
| TotalUnusualItemsExcludingGoodwill | -3.27M | 11.06M | 5.46M | -60.96M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.77M | -38.37M | -44.43M | -91.56M |
| ReconciledDepreciation | 284.00K | 1.75M | 1.80M | 2.10M |
| ReconciledCostOfRevenue | 254.00K | 0.00 | 0.00 | |
| EBITDA | -21.73M | -34.58M | -39.97M | -83.20M |
| EBIT | -22.01M | -36.33M | -41.77M | -85.31M |
| NetInterestIncome | -2.52M | -1.43M | -2.36M | -5.55M |
| InterestExpense | 2.52M | 1.43M | 2.36M | 5.55M |
| NormalizedIncome | -21.91M | -48.05M | -49.21M | -38.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.77M | -38.37M | -44.43M | -91.56M |
| TotalExpenses | 18.70M | 47.47M | 30.38M | 24.54M |
| TotalOperatingIncomeAsReported | -18.70M | -47.47M | -30.38M | -24.54M |
| DilutedAverageShares | 19.70M | 14.06M | 13.27M | 11.81M |
| BasicAverageShares | 19.70M | 14.06M | 13.27M | 11.81M |
| DilutedEPS | -1.26 | -2.73 | -3.35 | -7.74 |
| BasicEPS | -1.26 | -2.73 | -3.35 | -7.74 |
| DilutedNIAvailtoComStockholders | -24.77M | -38.37M | -44.43M | -91.56M |
| NetIncomeCommonStockholders | -24.77M | -38.37M | -44.43M | -91.56M |
| NetIncome | -24.77M | -38.37M | -44.43M | -91.56M |
| NetIncomeIncludingNoncontrollingInterests | -24.77M | -38.37M | -44.43M | -91.56M |
| NetIncomeContinuousOperations | -24.77M | -38.37M | -44.43M | -91.56M |
| TaxProvision | 240.00K | 613.00K | 301.00K | 705.00K |
| PretaxIncome | -24.53M | -37.76M | -44.13M | -90.86M |
| OtherIncomeExpense | -3.32M | 11.14M | -11.39M | -60.77M |
| OtherNonOperatingIncomeExpenses | -47.00K | 82.00K | -16.85M | 195.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | -3.27M | 11.06M | 5.46M | -60.96M |
| NetNonOperatingInterestIncomeExpense | -2.52M | -1.43M | -2.36M | -5.55M |
| InterestExpenseNonOperating | 2.52M | 1.43M | 2.36M | 5.55M |
| OperatingIncome | -18.70M | -47.47M | -30.38M | -24.54M |
| OperatingExpense | 18.44M | 47.47M | 30.38M | 24.54M |
| ResearchAndDevelopment | 10.46M | 39.99M | 17.62M | 10.71M |
| SellingGeneralAndAdministration | 7.98M | 7.48M | 12.77M | 13.82M |
| GeneralAndAdministrativeExpense | 7.98M | 7.48M | 12.77M | 13.82M |
| OtherGandA | 4.80M | 3.86M | 6.61M | 8.96M |
| SalariesAndWages | 3.19M | 3.62M | 6.15M | 4.87M |
| GrossProfit | -254.00K | 0.00 | 0.00 | |
| CostOfRevenue | 254.00K | 0.00 | 0.00 | |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 31.53M | 14.64M | 13.67M | 13.22M |
| ShareIssued | 31.53M | 14.64M | 13.67M | 13.22M |
| NetDebt | 21.41M | 12.88M | 7.37M | |
| TotalDebt | 45.53M | 18.96M | 28.47M | 26.52M |
| TangibleBookValue | -23.83M | -6.40M | 26.28M | 46.80M |
| InvestedCapital | 41.45M | 12.55M | 56.47M | 76.76M |
| WorkingCapital | 7.18M | 12.08M | 53.38M | 70.33M |
| NetTangibleAssets | -23.83M | -6.40M | 26.28M | 46.80M |
| CommonStockEquity | -4.08M | -6.40M | 28.00M | 50.23M |
| TotalCapitalization | 26.99M | 12.55M | 56.47M | 75.13M |
| TotalEquityGrossMinorityInterest | -4.08M | -6.40M | 28.00M | 50.23M |
| StockholdersEquity | -4.08M | -6.40M | 28.00M | 50.23M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 1.00K | -350.00K | 0.00 |
| OtherEquityAdjustments | 1.00K | -350.00K | ||
| RetainedEarnings | -486.07M | -461.30M | -422.93M | -378.49M |
| AdditionalPaidInCapital | 481.68M | 454.76M | 451.15M | 428.61M |
| CapitalStock | 315.00K | 135.00K | 126.00K | 122.00K |
| CommonStock | 315.00K | 135.00K | 126.00K | 122.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 48.68M | 32.66M | 38.83M | 41.27M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 31.07M | 19.14M | 29.77M | 28.33M |
| OtherNonCurrentLiabilities | 188.00K | 1.30M | 3.44M | |
| LongTermDebtAndCapitalLeaseObligation | 31.07M | 18.96M | 28.47M | 24.90M |
| LongTermDebt | 31.07M | 18.96M | 28.47M | 24.90M |
| CurrentLiabilities | 17.61M | 13.52M | 9.06M | 12.94M |
| OtherCurrentLiabilities | 240.00K | 761.00K | 1.94M | 9.05M |
| CurrentDebtAndCapitalLeaseObligation | 14.46M | 1.63M | ||
| CurrentDebt | 14.46M | 1.63M | ||
| OtherCurrentBorrowings | 14.46M | 1.63M | ||
| PayablesAndAccruedExpenses | 2.90M | 12.76M | 7.12M | 2.26M |
| CurrentAccruedExpenses | 2.65M | 7.76M | 4.35M | 1.17M |
| Payables | 251.00K | 5.00M | 2.77M | 1.10M |
| TotalTaxPayable | 0.00 | 221.00K | ||
| IncomeTaxPayable | 0.00 | 221.00K | ||
| AccountsPayable | 251.00K | 5.00M | 2.77M | 878.00K |
| TotalAssets | 44.59M | 26.26M | 66.83M | 91.51M |
| TotalNonCurrentAssets | 19.81M | 663.00K | 4.39M | 8.24M |
| OtherNonCurrentAssets | 39.00K | 612.00K | 2.60M | 4.72M |
| GoodwillAndOtherIntangibleAssets | 19.75M | 0.00 | 1.72M | 3.44M |
| NetPPE | 23.00K | 51.00K | 69.00K | 91.00K |
| AccumulatedDepreciation | -340.00K | -315.00K | -284.00K | -286.00K |
| GrossPPE | 363.00K | 366.00K | 353.00K | 377.00K |
| Leases | 148.00K | 148.00K | 148.00K | 148.00K |
| OtherProperties | 86.00K | |||
| MachineryFurnitureEquipment | 215.00K | 218.00K | 205.00K | 143.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 24.79M | 25.60M | 62.44M | 83.27M |
| OtherCurrentAssets | 65.00K | |||
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 531.00K | 1.43M | 1.22M | 680.00K |
| Receivables | 66.00K | 233.00K | 420.00K | 1.21M |
| TaxesReceivable | 66.00K | 233.00K | 420.00K | 915.00K |
| AccruedInterestReceivable | 55.00K | 290.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 24.12M | 23.93M | 60.80M | 81.38M |
| OtherShortTermInvestments | 0.00 | 17.86M | 39.71M | 53.94M |
| CashAndCashEquivalents | 24.12M | 6.07M | 21.09M | 27.45M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -26.77M | -39.34M | -18.54M | -15.90M |
| RepaymentOfDebt | 0.00 | 0.00 | -2.25M | -6.52M |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 26.69M | 1.03M | 433.00K | 89.64M |
| CapitalExpenditure | -2.00K | -13.00K | -62.00K | -61.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 22.00K | 416.00K |
| IncomeTaxPaidSupplementalData | 220.00K | 401.00K | 821.00K | 435.00K |
| EndCashPosition | 24.16M | 6.11M | 21.13M | 27.51M |
| BeginningCashPosition | 6.11M | 21.13M | 27.51M | 14.82M |
| EffectOfExchangeRateChanges | -75.00K | -61.00K | -50.00K | 4.00K |
| ChangesInCash | 18.13M | -14.96M | -6.33M | 12.69M |
| FinancingCashFlow | 26.69M | 1.03M | -1.82M | 83.13M |
| CashFlowFromContinuingFinancingActivities | 26.69M | 1.03M | -1.82M | 83.13M |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetCommonStockIssuance | 26.69M | 1.03M | 433.00K | 89.64M |
| CommonStockIssuance | 26.69M | 1.03M | 433.00K | 89.64M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -2.25M | -6.52M |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -2.25M | -6.52M |
| LongTermDebtPayments | 0.00 | 0.00 | -2.25M | -6.52M |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 18.21M | 23.34M | 13.96M | -54.59M |
| CashFlowFromContinuingInvestingActivities | 18.21M | 23.34M | 13.96M | -54.59M |
| NetInvestmentPurchaseAndSale | 18.21M | 23.35M | 14.02M | -54.53M |
| SaleOfInvestment | 30.60M | 64.53M | 59.73M | 12.50M |
| PurchaseOfInvestment | -12.39M | -41.18M | -45.71M | -67.03M |
| NetPPEPurchaseAndSale | -2.00K | -13.00K | -62.00K | -61.00K |
| PurchaseOfPPE | -2.00K | -13.00K | -62.00K | -61.00K |
| OperatingCashFlow | -26.77M | -39.33M | -18.47M | -15.84M |
| CashFlowFromContinuingOperatingActivities | -26.77M | -39.33M | -18.47M | -15.84M |
| ChangeInWorkingCapital | -12.73M | 2.76M | 2.31M | -440.00K |
| ChangeInOtherWorkingCapital | 155.00K | 271.00K | -510.00K | 271.00K |
| ChangeInOtherCurrentLiabilities | -385.00K | -354.00K | -708.00K | -1.11M |
| ChangeInOtherCurrentAssets | 17.00K | 322.00K | 0.00 | -8.00K |
| ChangeInPayablesAndAccruedExpense | -9.86M | 5.71M | 5.08M | -599.00K |
| ChangeInAccruedExpense | -5.11M | 3.49M | 3.19M | -662.00K |
| ChangeInPayable | -4.75M | 2.22M | 1.90M | 63.00K |
| ChangeInAccountPayable | -4.75M | 2.22M | 1.90M | 63.00K |
| ChangeInPrepaidAssets | -2.66M | -3.19M | -1.55M | 1.01M |
| OtherNonCashItems | 7.17M | 5.95M | 5.38M | 8.14M |
| StockBasedCompensation | 363.00K | 784.00K | 22.11M | 4.32M |
| AmortizationOfSecurities | -352.00K | -1.15M | -183.00K | 636.00K |
| DepreciationAmortizationDepletion | 284.00K | 1.75M | 1.80M | 2.10M |
| DepreciationAndAmortization | 284.00K | 1.75M | 1.80M | 2.10M |
| AmortizationCashFlow | 254.00K | 1.72M | 1.72M | 1.71M |
| AmortizationOfIntangibles | 254.00K | 1.72M | 1.72M | 1.71M |
| Depreciation | 30.00K | 31.00K | 84.00K | 391.00K |
| OperatingGainsLosses | 3.27M | -11.06M | -5.46M | 60.96M |
| GainLossOnInvestmentSecurities | 3.27M | -11.06M | -5.46M | 60.96M |
| NetIncomeFromContinuingOperations | -24.77M | -38.37M | -44.43M | -91.56M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ITRM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|